These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22898727)

  • 21. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    Luo XD; Chen XF; Zhou Y; Chen XP
    J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in serum alanine aminotransferase levels in telbivudine versus lamivudine treatment for chronic hepatitis B: a meta-analysis.
    Dai M; Xiao GM; Wang FL; Zhang JS; Li YM; Yang HZ
    J Int Med Res; 2015 Apr; 43(2):161-72. PubMed ID: 25687498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil.
    Li Y; Zhang Y; Wang JP; Lian JQ; Bai XF
    J Viral Hepat; 2013 Apr; 20 Suppl 1():46-51. PubMed ID: 23458524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study.
    Yang X; Li J; Liu J; Gao M; Zhou L; Lu W
    Medicine (Baltimore); 2017 Jun; 96(23):e7064. PubMed ID: 28591041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
    Vassiliadis TG; Giouleme O; Koumerkeridis G; Koumaras H; Tziomalos K; Patsiaoura K; Grammatikos N; Mpoumponaris A; Gkisakis D; Theodoropoulos K; Panderi A; Katsinelos P; Eugenidis N
    J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
    Hou J; Yin YK; Xu D; Tan D; Niu J; Zhou X; Wang Y; Zhu L; He Y; Ren H; Wan M; Chen C; Wu S; Chen Y; Xu J; Wang Q; Wei L; Chao G; Constance BF; Harb G; Brown NA; Jia J
    Hepatology; 2008 Feb; 47(2):447-54. PubMed ID: 18080339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance.
    Wang G; Liu Y; Qiu P; Zhou SF; Xu L; Wen P; Wen J; Xiao X
    Drug Des Devel Ther; 2015; 9():2839-46. PubMed ID: 26082614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Telbivudine versus lamivudine in patients with chronic hepatitis B.
    Lai CL; Gane E; Liaw YF; Hsu CW; Thongsawat S; Wang Y; Chen Y; Heathcote EJ; Rasenack J; Bzowej N; Naoumov NV; Di Bisceglie AM; Zeuzem S; Moon YM; Goodman Z; Chao G; Constance BF; Brown NA;
    N Engl J Med; 2007 Dec; 357(25):2576-88. PubMed ID: 18094378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
    Lu JJ; Liu K; Ma YJ; Wang J; Chen EQ; Tang H
    J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
    Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
    Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels.
    Shi H; Han Z; Liu J; Xue J; Zhang S; Zhu Z; Xia J; Huang M
    Med Sci Monit; 2017 Nov; 23():5230-5236. PubMed ID: 29095799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
    Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
    World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HBsAg seroclearance or seroconversion induced by peg-interferon alpha and lamivudine or adefovir combination therapy in chronic hepatitis B treatment: a meta-analysis and systematic review.
    Zhang Y; Chen B; Wang L; Chi J; Song S; Liu M; Zhao Z
    Rev Esp Enferm Dig; 2016 May; 108(5):263-70. PubMed ID: 27023755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy.
    Lee M; Oh S; Lee HJ; Yeum TS; Lee JH; Yu SJ; Kim HY; Yoon JH; Lee HS; Kim YJ
    J Viral Hepat; 2014 Dec; 21(12):873-81. PubMed ID: 24351112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of efficacy and renal safety of telbivudine and entecavir in treatment-naive elderly patients with chronic hepatitis B.
    Law ST; Lee MK; Li KK; Mok CK
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):193-8. PubMed ID: 26587867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B.
    Gane EJ; Wang Y; Liaw YF; Hou J; Thongsawat S; Wan M; Moon YM; Jia J; Chao YC; Niu J; Leung N; Samuel D; Hsu CW; Bao W; Lopez P; Avila C
    Liver Int; 2011 May; 31(5):676-84. PubMed ID: 21457439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of tenofovir-based rescue therapy in patients with lamivudine-resistant hepatitis B virus: A systematic review and meta-analysis.
    Wang HL; Lu X; Yang X; Ning Q
    Clin Res Hepatol Gastroenterol; 2016 Sep; 40(4):447-56. PubMed ID: 26621535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis.
    Sheng YJ; Liu JY; Tong SW; Hu HD; Zhang DZ; Hu P; Ren H
    Virol J; 2011 Aug; 8():393. PubMed ID: 21824397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Long-term efficacy and safety of telbivudine as monotherapy and as combination therapy with adefovir dipivoxil in HBeAg-positive chronic hepatitis B patients].
    Liu Y; Liu L; Peng D; Li W; Du Y; Jia T; Chang L; Li H
    Zhonghua Gan Zang Bing Za Zhi; 2014 Mar; 22(3):181-4. PubMed ID: 24824118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24-week therapy with pegylated interferon-α-2a].
    Luo XD; Chen XP; Chen R; Chen XF; Huang J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Apr; 24(4):241-5. PubMed ID: 27470620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.